Literature DB >> 16790365

Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand.

Yelena Glinka1, Yigang Chang, Gérald J Prud'homme.   

Abstract

DNA vaccination of autoimmune diabetes-prone NOD mice with unmodified target islet antigens, i.e., preproinsulin (PPIns) or glutamic acid decarboxylase 65 (GAD65), is poorly protective. However, in this study, we demonstrate protection against disease by covaccination with a mutant B7-1 molecule (B7-1wa) that binds the negative T cell regulator CTLA-4 (CD152), but not CD28. Codelivery of plasmids encoding a PPIns-GAD65 fusion construct and B7-1wa protected against both insulitis and diabetes. In vitro, the T cells of covaccinated mice had negative responses to both insulin and GAD65, and this was restored by adding blocking antibodies to transforming growth factor beta1 (TGF-beta1), suggesting a role for this cytokine. Adoptive transfer experiments revealed that DNA vaccination generated protective CD4(+) regulatory T cells (Tr) of either CD25(+) or CD25(-) phenotype. Furthermore, vaccinated mice had increased numbers of T cells with Tr-associated markers, such as CTLA-4, Foxp3, and membrane-bound TGF-beta1. Tr cells inhibited the responses of diabetogenic T cells to islet antigens, and depletion of T cells expressing membrane-bound TGF-beta1 abolished the suppressive effect. Thus, selective engagement of CTLA-4 during islet-antigen DNA vaccination induces Tr cells that protect against this autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790365     DOI: 10.1016/j.ymthe.2006.03.021

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

Review 1.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

Review 2.  Harnessing regulatory T cells to suppress asthma: from potential to therapy.

Authors:  Alison N Thorburn; Philip M Hansbro
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-22       Impact factor: 6.914

3.  Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation.

Authors:  Nicolas Perez; Subha Karumuthil-Melethil; Ruobing Li; Bellur S Prabhakar; Mark J Holterman; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

4.  Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes.

Authors:  Subha Karumuthil-Melethil; Nicolas Perez; Ruobing Li; Bellur S Prabhakar; Mark J Holterman; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

5.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

Review 6.  Antigen-specific therapeutic approaches in Type 1 diabetes.

Authors:  Xavier Clemente-Casares; Sue Tsai; Carol Huang; Pere Santamaria
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

7.  Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.

Authors:  Gérald J Prud'homme; Yelena Glinka; Anna Toulina; Olga Ace; Venkateswaran Subramaniam; Serge Jothy
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

Review 8.  Innate and adaptive immunity for the pathobiology of Parkinson's disease.

Authors:  David K Stone; Ashley D Reynolds; R Lee Mosley; Howard E Gendelman
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 9.  Regulatory T Cells in Allergy and Asthma.

Authors:  Elena Martín-Orozco; María Norte-Muñoz; Javier Martínez-García
Journal:  Front Pediatr       Date:  2017-05-23       Impact factor: 3.418

10.  Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity.

Authors:  Yelena Glinka; Gérald J Prud'homme
Journal:  J Leukoc Biol       Date:  2008-04-24       Impact factor: 4.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.